Sporadic Migraine
Conditions
Brief summary
Anodal tDCS increases the excitability of the cerebral cortex and its daily application during intercritical phase, may have a therapeutic effect in episodic migraine.
Detailed description
During the interictal phase, the cerebral cortex is characterised by hyperresponsiveness to repeated sensory stimuli, manifested by a lack of habituation or adaptation of cortical evoked responses. Such habituation deficit can be shown in the visual cortex by the study of visual evoked potentials (VEP) and it is possibly explained by a reduction in the cortical pre-activation level due to thalamo-cortical dysrhythmia. In healthy subjects and in migraineurs between attacks, anodal tDCS increases VEP habituation and 1st block amplitude. In a proof-of-concept trial, the investigators have shown in 10 episodic migraine without aura patients that 2 weekly 15-minute sessions for 8 weeks of anodal tDCS over the visual cortex significantly decreased attack frequency, migraine days, attack duration and acute medication intake for more than 4 weeks after the last treatment session. This randomized trial was designed to prove the preventive effect in episodic migraine of anodal tDCS over the visual cortex compared to sham stimulation.
Interventions
DEVICECefaly tDCS
Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
DEVICEsham Cefaly tDCS
2mA during 30sec
Sponsors
University of Liege
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* diagnosis of episodic migraine with (ICHD III beta 1.2.1) or without aura (ICHD III beta 1.1)
Exclusion criteria
* preventive treatment * others diseases or contraindications to tDCS (epilepsy, pacemaker, metal prosthetics)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Migraine frequency | 6 months | The investigators evaluate the migraine frequency at baseline (2 months), during the treatment and 2 months after its end. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Migraine intensity | 6 months | The investigators evaluate migraine intensity at baseline, during the treatment and 2 months after its end. |
| Acute medication intake | 6 months | The investigators evaluate acute medication intake at baseline, during the treatment and 2 months after its end. |
| Attack duration | 6 months | The investigators evaluate attack duration at baseline, during the treatment and 2 months after its end. |
| Score on psychological scales | 6 Months | The investigators evaluate score on psychological scales at baseline, during the treatment and 2 months after its end. |
Countries
Belgium
Outcome results
None listed